201 related articles for article (PubMed ID: 901735)
1. Lignocaine kinetics in cardiac patients and aged subjects.
Nation RL; Triggs EJ; Selig M
Br J Clin Pharmacol; 1977 Aug; 4(4):439-48. PubMed ID: 901735
[TBL] [Abstract][Full Text] [Related]
2. Effect of erythromycin and itraconazole on the pharmacokinetics of intravenous lignocaine.
Isohanni MH; Neuvonen PJ; Palkama VJ; Olkkola KT
Eur J Clin Pharmacol; 1998 Sep; 54(7):561-5. PubMed ID: 9832299
[TBL] [Abstract][Full Text] [Related]
3. Effect of the CYP3A4 inhibitor erythromycin on the pharmacokinetics of lignocaine and its pharmacologically active metabolites in subjects with normal and impaired liver function.
Orlando R; Piccoli P; De Martin S; Padrini R; Palatini P
Br J Clin Pharmacol; 2003 Jan; 55(1):86-93. PubMed ID: 12534644
[TBL] [Abstract][Full Text] [Related]
4. The pharmacokinetics and pharmacodynamics of lignocaine and MEGX in healthy subjects.
Thomson AH; Elliott HL; Kelman AW; Meredith PA; Whiting B
J Pharmacokinet Biopharm; 1987 Apr; 15(2):101-15. PubMed ID: 3612496
[TBL] [Abstract][Full Text] [Related]
5. Lignocaine and indocyanine green kinetics in patients following myocardial infarction.
Bax ND; Tucker GT; Woods HF
Br J Clin Pharmacol; 1980 Oct; 10(4):353-61. PubMed ID: 7448106
[TBL] [Abstract][Full Text] [Related]
6. The effect of age on plasma MEGX concentrations.
Orlando R; Palatini P
Br J Clin Pharmacol; 1997 Aug; 44(2):206-8. PubMed ID: 9278213
[TBL] [Abstract][Full Text] [Related]
7. Plasma concentrations of lignocaine and its metabolites during fibreoptic bronchoscopy.
Jones DA; McBurney A; Stanley PJ; Tovey C; Ward JW
Br J Anaesth; 1982 Aug; 54(8):853-7. PubMed ID: 7104134
[TBL] [Abstract][Full Text] [Related]
8. Protein binding and disposition of lignocaine in the elderly.
Cusack B; O'Malley K; Lavan J; Noel J; Kelly JG
Eur J Clin Pharmacol; 1985; 29(3):323-9. PubMed ID: 4076329
[TBL] [Abstract][Full Text] [Related]
9. The lignocaine metabolite (MEGX) liver function test and P-450 induction in humans.
Reichel C; Skodra T; Nacke A; Spengler U; Sauerbruch T
Br J Clin Pharmacol; 1998 Dec; 46(6):535-9. PubMed ID: 9862241
[TBL] [Abstract][Full Text] [Related]
10. Continuous infusion of lidocaine in patients with cardiac arrhythmias. Unpredictability of plasma concentrations.
Sawyer DR; Ludden TM; Crawford MH
Arch Intern Med; 1981 Jan; 141(1):43-5. PubMed ID: 7447583
[TBL] [Abstract][Full Text] [Related]
11. Lignocaine: a new technique for intravenous administration.
Levy RA; Charuzi Y; Mandel WJ
Br Heart J; 1977 Sep; 39(9):1026-8. PubMed ID: 907767
[TBL] [Abstract][Full Text] [Related]
12. Clinical pharmacokinetics of lignocaine.
Benowitz NL; Meister W
Clin Pharmacokinet; 1978; 3(3):177-201. PubMed ID: 350470
[TBL] [Abstract][Full Text] [Related]
13. The effect of liver disease and food on plasma MEGX concentrations.
Pritchard-Davies R; Gross AS; Shenfield GM
Br J Clin Pharmacol; 1994 Mar; 37(3):298-301. PubMed ID: 8198941
[TBL] [Abstract][Full Text] [Related]
14. Correlation between midazolam and lignocaine pharmacokinetics and MEGX formation in healthy volunteers.
Swart EL; van der Hoven B; Groeneveld AB; Touw DJ; Danhof M
Br J Clin Pharmacol; 2002 Feb; 53(2):133-9. PubMed ID: 11851636
[TBL] [Abstract][Full Text] [Related]
15. General derivation of the ideal intravenous drug input required to achieve and maintain a constant plasma drug concentration. Theoretical application to lignocaine therapy.
Vaughan DP; Tucker GT
Eur J Clin Pharmacol; 1976; 10(6):433-40. PubMed ID: 1001359
[TBL] [Abstract][Full Text] [Related]
16. Logical approach to lignocaine therapy.
Aps C; Bell JA; Jenkins BS; Poole-Wilson PA; Reynolds F
Br Med J; 1976 Jan; 1(6000):13-5. PubMed ID: 1247716
[TBL] [Abstract][Full Text] [Related]
17. Impaired Lignocaine metabolism in patients with myocardial infarction and cardiac failure.
Prescott LF; Adjepon-Yamoah KK; Talbot RG
Br Med J; 1976 Apr; 1(6015):939-41. PubMed ID: 1268491
[TBL] [Abstract][Full Text] [Related]
18. Excretion of lignocaine and its metabolite monoethylglycinexylidide in breast milk following its use in a dental procedure. A case report.
Lebedevs TH; Wojnar-Horton RE; Yapp P; Roberts MJ; Dusci LJ; Hackett LP; Ilett K
J Clin Periodontol; 1993 Sep; 20(8):606-8. PubMed ID: 8408724
[TBL] [Abstract][Full Text] [Related]
19. Influence of congestive heart failure on blood vessels of lidocaine and its active monodeethylated metabolite.
Halkin H; Meffin P; Melmon KL; Rowland M
Clin Pharmacol Ther; 1975 Jun; 17(6):669-76. PubMed ID: 1139858
[TBL] [Abstract][Full Text] [Related]
20. Extrahepatic production of the lignocaine metabolite monoethylglycinexylidide (MEGX).
Sallie RW; Tredger JM; Williams R
Biopharm Drug Dispos; 1992 Oct; 13(7):555-8. PubMed ID: 1489946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
